Table 1. Baseline characteristics as per randomized study drug and platelet count quartiles.
| Characteristic | Quartile 1 ( n = 997) |
Quartile 2 ( n = 1,003) |
Quartile 3 ( n = 961) |
Quartile 4 ( n = 982) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticagrelor ( n = 485) |
Prasugrel ( n = 512) |
p -Value | Ticagrelor ( n = 500) |
Prasugrel ( n = 503) |
p -Value | Ticagrelor ( n = 482) |
Prasugrel ( n = 479) |
p -Value | Ticagrelor ( n = 499) |
Prasugrel ( n = 483) |
p -Value | |
| Age, y | 67.2 ± 11.8 | 66.9 ± 11.3 | 0.631 | 64.5 ± 12.1 | 65.2 ± 12.5 | 0.334 | 63.7 ± 11.4 | 63.4 ± 12.3 | 0.691 | 62.8 ± 12.3 | 62.9 ± 11.8 | 0.973 |
| Sex | 0.171 | 0.607 | 0.412 | 0.520 | ||||||||
| Female, no. (%) | 55 (11.3) | 74 (14.5) | 109 (21.8) | 102 (20.3) | 133 (27.6) | 120 (25.1) | 170 (34.1) | 175 (36.2) | ||||
| Diabetes, no. (%) | 117 (24.1) | 138 (27.0) | 0.342 | 114 (22.8) | 105 (20.9) | 0.508 | 103 (21.4) | 85 (17.7) | 0.182 | 117 (23.4) | 99 (20.5) | 0.307 |
| Insulin-treated, no. (%) | 39 (8.0) | 50 (9.8) | 0.399 | 33 (6.6) | 27 (5.4) | 0.490 | 26 (5.4) | 26 (5.4) | >0.999 | 39 (7.8) | 32 (6.6) | 0.557 |
| Current smoker, no. (%) | 129/483 (26.7) | 146/508 (28.7) | 0.520 | 158 (31.6) | 159 (31.6) | >0.999 | 176/480 (36.7) | 158/477 (33.1) | 0.279 | 200/494 (40.5) | 192/482 (39.8) | 0.887 |
| Arterial hypertension, no. (%) | 353/483 (73.1) | 375/511 (73.4) | 0.972 | 358 (71.6) | 353 (70.2) | 0.670 | 334/481 (69.4) | 313 (65.3) | 0.199 | 358 (71.7) | 324/481 (67.4) | 0.155 |
| Hypercholesterolemia, no. (%) | 289/484 (59.7) | 324 (63.3) | 0.275 | 306/499 (61.3) | 292 (58.1) | 0.322 | 291/481 (60.5) | 284/479 (59.4) | 0.782 | 273/498 (54.8) | 250/481 (52.0) | 0.408 |
| Prior myocardial infarction, no. (%) | 89 (18.4) | 110/511 (21.5) | 0.241 | 88 (17.6) | 81 (16.1) | 0.583 | 70/480 (14.6) | 65 (13.6) | 0.720 | 57 (11.4) | 63 (13.0) | 0.498 |
| Prior PCI, no. (%) | 137 (28.2) | 164/511 (32.1) | 0.210 | 123 (24.6) | 114 (22.7) | 0.517 | 98/481 (20.4) | 98 (20.5) | >0.999 | 89 (17.8) | 85 (17.6) | 0.989 |
| Prior CABG, no. (%) | 48 (9.9) | 62/511 (12.1) | 0.306 | 33 (6.6) | 33 (6.6) | >0.999 | 20/481 (4.2) | 19 (4.0) | >0.999 | 14 (2.8) | 15 (3.1) | 0.929 |
| Cardiogenic shock, no. (%) | 9 (1.9) | 8 (1.6) | 0.910 | 7 (1.4) | 7 (1.4) | >0.999 | 8 (1.7) | 7 (1.5) | >0.999 | 6 (1.2) | 12 (2.5) | 0.208 |
| Systolic blood pressure (mmHg) | 142 ± 24.2 | 142 ± 24.1 | 0.957 | 145 ± 25.1 | 144 ± 24.6 | 0.338 | 143 ± 25.5 | 144 ± 25.1 | 0.935 | 143 ± 25.4 | 143 ± 23.7 | 0.600 |
| Diastolic blood pressure (mmHg) | 80.7 ± 14.5 | 80.9 ± 13.2 | 0.876 | 83.2 ± 14.7 | 81.0 ± 13.9 | 0.016 | 81.5 ± 14.1 | 83.3 ± 14.3 | 0.056 | 82.1 ± 14.7 | 82.3 ± 13.8 | 0.846 |
| Heart rate, (beats/min) | 75.7 ± 16.1 | 73.9 ± 15.5 | 0.074 | 75.9 ± 15.6 | 75.0 ± 14.6 | 0.372 | 76.8 ± 15.5 | 76.6 ± 14.7 | 0.779 | 79.2 ± 16.2 | 78.5 ± 16.9 | 0.535 |
| Body mass index, (kg/m 2 ) | 27.8 ± 4.2 | 28.2 ± 4.4 | 0.140 | 28.0 ± 4.5 | 27.8 ± 4.5 | 0.462 | 27.5 ± 4.2 | 27.9 ± 4.4 | 0.161 | 27.8 ± 5.3 | 27.3 ± 4.3 | 0.169 |
| Weight <60 kg | 13/483 (2.7) | 16/504 (3.2) | 0.794 | 25 (5.0) | 29/500 (5.8) | 0.680 | 26/479 (5.4) | 19 (4.0) | 0.363 | 40/496 (8.1) | 29/479 (6.1) | 0.272 |
| Creatinine (µmol/L) | 92.0 ± 29.2 | 93.4 ± 32.8 | 0.487 | 89.5 ± 26.7 | 0.771 | 85.9 ± 25.8 | 86.3 ± 24.5 | 0.816 | 83.4 ± 25.7 | 83.1 ± 26.5 | 0.822 | |
| Diagnosis at admission | 0.739 | 0.946 | 0.612 | 0.980 | ||||||||
| Unstable angina | 77 (15.9) | 86 (16.8) | 72 (14.4) | 69 (13.7) | 56 (11.6) | 63 (13.2) | 42 (8.4) | 42 (8.7) | ||||
| NSTEMI | 232 (47.8) | 252 (49.2) | 235 (47.0) | 240 (47.7) | 225 (46.7) | 210 (43.8) | 231 (46.3) | 221 (45.8) | ||||
| STEMI | 176 (36.3) | 174 (34.0) | 193 (38.6) | 194 (38.6) | 201 (41.7) | 206 (43.0) | 226 (45.3) | 220 (45.5) | ||||
| Coronary angiography | 484 (99.8) | 510 (99.6) | >0.999 | 497 (99.4) | 503 (100) | 0.124 | 480 (99.6) | 478 (99.8) | >0.999 | 496 (99.4) | 481 (99.6) | >0.999 |
| Treatment strategy | 0.907 | 0.699 | 0.028 | 0.474 | ||||||||
| PCI | 395/484 (81.6) | 421 (82.2) | 405 (81.2) | 417 (82.9) | 397/481 (82.5) | 419 (87.5) | 435 (87.3) | 416/482 (86.3) | ||||
| CABG | 12/484 (2.5) | 14 (2.7) | 9 (1.8) | 10 (2.0) | 15/481 (3.1) | 5 (1.0) | 11 (2.2) | 7/482 (1.5) | ||||
| Conservative | 77/484 (15.9) | 77 (15.0) | 85 (17.0) | 76 (15.1) | 69/481 (14.3) | 55 (11.5) | 52 (10.4) | 59/482 (12.2) | ||||
Abbreviations: CABG, coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
Note: Data are mean ± standard deviation or counts (%).
Missing continuous data:
Q1 quartile: diastolic blood pressure: 4 patients (1 in the ticagrelor group, 3 in the prasugrel group), body mass index: 12 patients (3 in the ticagrelor group, 9 in the prasugrel group), heart rate: 1 patient in the ticagrelor group.
Q2 quartile: diastolic blood pressure: 5 patients (1 in the ticagrelor group, 4 in the prasugrel group), body mass index: 5 patients (2 in the ticagrelor group, 3 in the prasugrel group).
Q3 quartile: body mass index: 5 patients (4 in the ticagrelor group, 1 in the prasugrel group).
Q4 quartile: diastolic blood pressure: 2 patients (1 in each group), heart rate: 1 patient in the prasugrel group, body mass index: 7 patients (3 in the ticagrelor group, 4 in the prasugrel group)
The remaining continuous data were complete.